FIC CVD

FIC CVD is a discovery-stage small molecule program being developed by Nutshell Therapeutics for the treatment of cardiovascular disease (CVD). The 'FIC' designation in the company's pipeline indicates that the program is aimed at a 'First-in-Class' biological target, the specific identity of which has not yet been publicly disclosed. The program leverages Nutshell's proprietary allosteric drug discovery platform, which focuses on identifying small molecules that modulate protein function through non-orthosteric binding sites. This approach is intended to discover novel therapeutic interventions for cardiovascular indications where traditional orthosteric modulation may be challenging or insufficient.